Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | PGR | P06401 | 8/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.41 |
| ▸ | AR | P10275 | 2/20 | 0.40 |
| ▸ | XDH | P47989 | 2/20 | 0.35 |
| ▸ | PTGIR | P43119 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | LTC4S | Q16873 | 2/20 | 0.33 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.33 |
| ▸ | NOS3 | P29474 | 1/20 | 0.33 |
| ▸ | NOS1 | P29475 | 1/20 | 0.33 |
| ▸ | NOS2 | P35228 | 1/20 | 0.33 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1377442 | 1.00 | NPC1 (0.41) | NPC1RAB9APGRCYP2C19AR | |
| SCHEMBL1377609 | 0.89 | PGR (0.52) | PGRCYP2C19CYP2D6CYP2C9KCNH2 | |
| SCHEMBL1377611 | 0.89 | PGR (0.52) | PGRCYP2C19CYP2D6CYP2C9KCNH2 | |
| SCHEMBL13326538 | 0.87 | PGR (0.39) | NPC1RAB9APGRCYP2C19AR | |
| SCHEMBL3289466 | 0.86 | AR (0.58) | PGRARCYP2D6CYP2C9 | |
| SCHEMBL3289468 | 0.86 | AR (0.58) | PGRARCYP2D6CYP2C9 | |
| SCHEMBL1378894 | 0.85 | PGR (0.38) | NPC1RAB9APGRCYP2C19AR | |
| SCHEMBL13326539 | 0.85 | PGR (0.38) | NPC1RAB9APGRCYP2C19AR | |
| SCHEMBL1378496 | 0.85 | PGR (0.39) | NPC1RAB9APGRCYP2C19AR | |
| SCHEMBL3288273 | 0.85 | PGR (0.39) | NPC1RAB9APGRCYP2C19AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1725522-B1 | ANILINE DERIVATIVES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS | GLAXOSMITHKLINE LLC (US) | 2014-09-10 | — | — | EP | claimed |
| JP-4805909-B2 | — | — | 2011-11-02 | — | — | JP | claimed |
| US-7514470-B2 | Aniline derivatives as selective androgen receptor modulators | SMITHKLINE BEECHAM CORPORATION (US) | 2009-04-07 | — | — | US | claimed |
| US-20070191479-A1 | Aniline derivatives as selective androgen receptor modulators | GLAXOSMITHKLINE LLC | 2007-08-16 | — | — | US | claimed |
| EP-1725522-A1 | ANILINE DERIVATIVES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-11-29 | — | — | EP | claimed |
| WO-2005085185-A1 | ANILINE DERIVATIVES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-09-15 | — | — | WO | claimed |
| EP-1725522-B1 | ANILINE DERIVATIVES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS | GLAXOSMITHKLINE LLC (US) | 2014-09-10 | — | — | EP | disclosed |
| EP-1725522-B1 | ANILINE DERIVATIVES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS | GLAXOSMITHKLINE LLC (US) | 2014-09-10 | — | — | EP | disclosed |
| US-7723385-B2 | Aniline derivatives as selective androgen receptor modulators | GLAXOSMITHKLINE LLC (US) | 2010-05-25 | — | — | US | disclosed |
| US-7723385-B2 | Aniline derivatives as selective androgen receptor modulators | GLAXOSMITHKLINE LLC (US) | 2010-05-25 | — | — | US | disclosed |
| US-7723385-B2 | Aniline derivatives as selective androgen receptor modulators | GLAXOSMITHKLINE LLC (US) | 2010-05-25 | — | — | US | disclosed |
| US-20090163588-A1 | ANILINE DERIVATIVES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-06-25 | — | — | US | disclosed |
| US-20090163588-A1 | ANILINE DERIVATIVES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-06-25 | — | — | US | disclosed |
| US-7514470-B2 | Aniline derivatives as selective androgen receptor modulators | SMITHKLINE BEECHAM CORPORATION (US) | 2009-04-07 | — | — | US | disclosed |
| US-7514470-B2 | Aniline derivatives as selective androgen receptor modulators | SMITHKLINE BEECHAM CORPORATION (US) | 2009-04-07 | — | — | US | disclosed |
| US-20070191479-A1 | Aniline derivatives as selective androgen receptor modulators | GLAXOSMITHKLINE LLC | 2007-08-16 | — | — | US | disclosed |
| US-20070191479-A1 | Aniline derivatives as selective androgen receptor modulators | GLAXOSMITHKLINE LLC | 2007-08-16 | — | — | US | disclosed |
| US-20070191479-A1 | Aniline derivatives as selective androgen receptor modulators | GLAXOSMITHKLINE LLC | 2007-08-16 | — | — | US | disclosed |
| EP-1725522-A1 | ANILINE DERIVATIVES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-11-29 | — | — | EP | disclosed |
| WO-2005085185-A1 | ANILINE DERIVATIVES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-09-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163588-A1 | ANILINE DERIVATIVES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS | AR, NR3C2, NR5A1 | NPC1 2753/4885RAB9A 4846/4885PGR 24/4885 |
| US-20070191479-A1 | Aniline derivatives as selective androgen receptor modulators | AR, NR3C2, NR5A1 | NPC1 2753/4885RAB9A 4846/4885PGR 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.